Differences between normal and cml stem cells: Potential targets for clinical exploitation-Reference-Cited by-同舟云学术

Differences between normal and cml stem cells: Potential targets for clinical exploitation

Published:2009-06-04 Issue:S2 Volume:16 Page:77-83
ISSN:1066-5099
Container-title:STEM CELLS
language:en
Short-container-title:STEM CELLS

Author:

Eaves A. C.,Barnett M. J.,Ponchio L.,Cashman J. D.,Petzer A. L.,Eaves C. J.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,Molecular Medicine

Reference26 articles.

1. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia;Maguer-Satta;Blood,1996

2. Ichimaru M. Ishimaru T. Mikami M. Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki October 1950-December 1978 1981

3. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML;Deisseroth;Blood,1994

4. Growth characteristics of leukemic and normal hematopoietic cells in Ph1+ chronic myelogenous leukemia and effects of intensive treatment;Goto;Blood,1982

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability;OncoTargets and Therapy;2023-10

2. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy;Leukemia;2020-01-02

3. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells;Blood;2012-03-08

4. Target-specific cancer treatment: chronic granulocytic leukemia as a model;Transactions of the Royal Society of South Africa;2005-04

5. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays;Oncogene;2004-09